Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical development. The company is conducting preclinical work, with the aim of completing regulatory filings and initiating clinical studies as soon as possible in 2022.
“In our mission to deliver finite and curative therapies to individuals with HBV, we have always been committed to developing the most promising candidates, specifically those with the profile to achieve greater, and potentially complete, viral suppression in patients,” said William Delaney, PhD, chief scientific officer of Assembly Bio. “We believe ABI-4334 has a best-in-class preclinical profile with single-digit nanomolar potency against the production of new virus and also the formation of cccDNA. We’re excited to further evaluate this compound and its potential, as we plan for the start of clinical studies next year.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?